Systematic Analysis of Gene Expression in Lung Adenocarcinoma and Squamous Cell Carcinoma with a Case Study of FAM83A and FAM83B

被引:14
|
作者
Cai, Ling [1 ,2 ,3 ]
Luo, Danni [1 ]
Yao, Bo [1 ]
Yang, Donghan M. [1 ]
Lin, Shin Yi [1 ]
Girard, Luc [4 ]
DeBerardinis, Ralph J. [2 ,3 ]
Minna, John D. [4 ]
Xie, Yang [1 ]
Xiao, Guanghua [1 ]
机构
[1] UT Southwestern Med Ctr, Simmons Comprehens Canc Ctr, Dept Populat & Data Sci, Quantitat Biomed Res Ctr, 5323 Harry Hines Blvd, Dallas, TX 75390 USA
[2] UT Southwestern Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA
[3] UT Southwestern Med Ctr, Childrens Med Ctr Res Inst, Dallas, TX 75390 USA
[4] Univ Texas Southwestern Med Ctr Dallas, Simmons Comprehens Canc Ctr, Dept Internal Med, Hamon Ctr Therapeut Oncol Res,Dept Pharmacol, Dallas, TX 75390 USA
来源
CANCERS | 2019年 / 11卷 / 06期
关键词
lung cancer; gene expression difference between tumor and normal; survival association analysis; systematic analysis; meta-analysis; FAM83; CLASS-II EXPRESSION; CANCER; SURVIVAL; EGFR;
D O I
10.3390/cancers11060886
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: In our previous study, we constructed a Lung Cancer Explorer (LCE) database housing lung cancer-specific expression data and clinical data from over 6700 patients in 56 studies. Methods: Using this dataset of the largest collection of lung cancer gene expression along with our meta-analysis method, we systematically interrogated the association between gene expression and overall survival as well as the expression difference between tumor and normal (adjacent non-malignant tissue) samples in lung adenocarcinoma (ADC) and lung squamous cell carcinoma (SQCC). A case study for FAM83A and FAM83B was performed as a demonstration for hypothesis testing with our database. Results: We showed that the reproducibility of results across studies varied by histological subtype and analysis type. Genes and pathways unique or common to the two histological subtypes were identified and the results were integrated into LCE to facilitate user exploration. In our case study, we verified the findings from a previous study on FAM83A and FAM83B in non-small cell lung cancer. Conclusions: This study used gene expression data from a large cohort of patients to explore the molecular differences between lung ADC and SQCC.
引用
收藏
页数:17
相关论文
共 50 条
  • [1] FAM83A and FAM83B: candidate oncogenes and TKI resistance mediators
    Grant, Steven
    JOURNAL OF CLINICAL INVESTIGATION, 2012, 122 (09): : 3048 - 3051
  • [2] FAM83B is a novel biomarker for diagnosis and prognosis of lung squamous cell carcinoma
    Okabe, Naoyuki
    Ezaki, Junji
    Yamaura, Takumi
    Muto, Satoshi
    Osugi, Jun
    Tamura, Hirosumi
    Imai, Jun-Ichi
    Ito, Emi
    Yanagisawa, Yuka
    Honma, Reiko
    Gotoh, Mitsukazu
    Watanabe, Shinya
    Waguri, Satoshi
    Suzuki, Hiroyuki
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2015, 46 (03) : 999 - 1006
  • [3] FAM83A and FAM83A-AS1 both play oncogenic roles in lung adenocarcinoma
    Wang, Gaoming
    Li, Xiaokun
    Yao, Yu
    Jiang, Zhisheng
    Zhou, Hai
    Xie, Kai
    Luo, Jing
    Shen, Yi
    ONCOLOGY LETTERS, 2021, 21 (04)
  • [4] LncRNA FAM83A-AS1 promotes lung adenocarcinoma progression by enhancing the pre-mRNA stability of FAM83A
    Wang, Wenyi
    Zhao, Zhunlin
    Xu, Chun
    Li, Chang
    Ding, Cheng
    Chen, Jun
    Chen, Tengfei
    Zhao, Jun
    THORACIC CANCER, 2021, 12 (10) : 1495 - 1502
  • [5] FAM83A drives PD-L1 expression via ERK signaling and FAM83A/PD-L1 co-expression correlates with poor prognosis in lung adenocarcinoma
    Zhou, Fengrui
    Wang, Xin
    Liu, Fang
    Meng, Qingwei
    Yu, Yan
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2020, 25 (09) : 1612 - 1623
  • [6] FAM83B is involved in thyroid cancer cell differentiation and migration
    Cirello, Valentina
    Grassi, Elisa Stellaria
    Pogliaghi, Gabriele
    Ghiandai, Viola
    Ermellino, Laura
    Muzza, Marina
    Gazzano, Giacomo
    Persani, Luca
    Colombo, Carla
    Fugazzola, Laura
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [7] FAM83A antisense RNA 1 (FAM83A-AS1) silencing impairs cell proliferation and induces autophagy via MET-AMPKalpha signaling in lung adenocarcinoma
    Zhao, Huijie
    Wang, Yinghan
    Wu, Xing
    Zeng, Xaofei
    Lin, Baoyue
    Hu, Shengmin
    Zhang, Shenglin
    Li, Yu
    Zhou, Zhiqing
    Zhou, Yujie
    Du, Changzheng
    Beer, David G.
    Bai, Shengbin
    Chen, Guoan
    BIOENGINEERED, 2022, 13 (05) : 13312 - 13327
  • [8] High Expression of FAM83B Predicts Poor Prognosis in Patients with Pancreatic Ductal Adenocarcinoma and Correlates with Cell Cycle and Cell Proliferation
    Shen, Chao-qin
    Yan, Ting-Ting
    Liu, Wei
    Zhu, Xiao-qiang
    Tian, Xiang-long
    Fu, Xue-liang
    Hua, Rong
    Zhang, Jun-feng
    Huo, Yan-miao
    Liu, De-jun
    Yang, Jian-yu
    Sun, Yong-Wei
    Fang, Jing-Yuan
    Chen, Hao-Yan
    Hong, Jie
    JOURNAL OF CANCER, 2017, 8 (16): : 3154 - 3165
  • [9] Increased expression of FAM83B predicts poor prognosis in patients with gastric cancer
    Xiang, Xiao-Jun
    Zhong, Rui-Yi
    Tu, Qi
    Fang, Zi-Ling
    Feng, Miao
    Xiong, Jian-Ping
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2016, 9 (12): : 12492 - 12501
  • [10] FAM83B promotes the invasion of primary lung adenocarcinoma via PI3K/AKT/NF-κB pathway
    Zhang, Jing
    Wang, Jiajia
    Yue, Ke
    Li, Panpan
    Shen, Wenping
    Qiao, Xiaowen
    Wang, Yan
    Wu, Xiaojuan
    BMC PULMONARY MEDICINE, 2023, 23 (01)